Literature DB >> 23118824

The Role of EGFR and HER2- Activating Mutations in Maxillary Sinus Cancer.

Patricia Ene1, Radu Cristian Popescu, Stefan Voiculescu, Razvan Scaunasu, Bogdan Popescu, Raluca Grigore, Razvan Ene, Catalin Cîrstoiu.   

Abstract

Head and neck cancers account for less than 5% of all cancers worldwide and for less than 1% of all cancer deaths in Romania. Sinonasal squamous cell carcinomas are malignant tumors with origin in the respiratory mucosa of the paranasal sinuses and the nasal cavity. Because of the proximity to different important structures such as the brain, the eye the relevance of a multimodal therapy is well known. We take into discussion not only the most recent data from novel agents targeting EGF receptor (EGFR), VEGF and p53 pathways for the management of sinonasal cancer, but also further development of multimodal approach, and the use of biomarkers to appreciate the progression of the disease and the prognostic and overall survival rate in clinical practice. EGFR alterations have been implicated in the pathogenesis and progression of many malignancies. EGFR overexpression has been studied extensively regarding its clinical use but the results are yet to be analyzed.

Entities:  

Keywords:  EGFR; head and neck cancers; overexpression; sinonasal cancer

Year:  2012        PMID: 23118824      PMCID: PMC3484801     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  27 in total

1.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Signal transduction and oncogenesis by ErbB/HER receptors.

Authors:  Mina D Marmor; Kochupurakkal Bose Skaria; Yosef Yarden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

Review 3.  Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications.

Authors:  F Ciardiello; G Tortora
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

4.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

Review 5.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

6.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

7.  Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

Authors:  Yang Lu; Xinqun Li; Ke Liang; Rodney Luwor; Zahid H Siddik; Gordon B Mills; John Mendelsohn; Zhen Fan
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Authors:  Pablo Matar; Federico Rojo; Raúl Cassia; Gema Moreno-Bueno; Serena Di Cosimo; José Tabernero; Marta Guzmán; Sonia Rodriguez; Joaquín Arribas; José Palacios; José Baselga
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

9.  Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Authors:  Shyhmin Huang; Eric A Armstrong; Sergio Benavente; Prakash Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Authors:  Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

View more
  1 in total

1.  Successful salvage treatment of refractory recurrence of maxillary sinus carcinoma using image-guided high-dose-rate interstitial brachytherapy.

Authors:  Yin Zhang; Ning Wu; Zhipeng Zhao; Qianqian Chen; Guanghui Cheng
Journal:  J Contemp Brachytherapy       Date:  2018-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.